An Automated, Closed System For Rapid Manufacturing Of Engineered T-Cells

The remarkable achievements of chimeric antigen receptor (CAR) T cell therapy in treating hematologic malignancies have sparked significant interest in the field of immunotherapy. Explore an innovative approach that has demonstrated the potential of genetically modified T cells to target not only blood cancers but also solid tumors and infectious diseases. Despite these promising advancements, the current manufacturing processes for CAR-T cells remain intricate and labor-intensive.

In this webinar, delve into the new T Cell Transduction – Large Scale (TCT-LS) process designed for the CliniMACS Prodigy® Platform and a comprehensive overview of the process details that highlights its unique features and differentiators. We will also discuss the limitations of the TCT-LS process and guide you on selecting the most suitable process type for your specific needs.

Watch to gain valuable insights into these cutting-edge developments and learn how they can be applied to enhance your immunotherapeutic strategies.